Interleukin-7 receptor α mutational activation can initiate precursor B-cell acute lymphoblastic leukemia

白细胞介素-7受体α突变激活可启动前体B细胞急性淋巴细胞白血病。

阅读:9
作者:Afonso R M Almeida,João L Neto,Ana Cachucho,Mayara Euzébio,Xiangyu Meng,Rathana Kim,Marta B Fernandes,Beatriz Raposo,Mariana L Oliveira,Daniel Ribeiro,Rita Fragoso,Priscila P Zenatti,Tiago Soares,Mafalda R de Matos,Juliana Ronchi Corrêa,Mafalda Duque,Kathryn G Roberts,Zhaohui Gu,Chunxu Qu,Clara Pereira,Susan Pyne,Nigel J Pyne,Vasco M Barreto,Isabelle Bernard-Pierrot,Emannuelle Clappier,Charles G Mullighan,Ana R Grosso,J Andrés Yunes #,João T Barata #

Abstract

Interleukin-7 receptor α (encoded by IL7R) is essential for lymphoid development. Whether acute lymphoblastic leukemia (ALL)-related IL7R gain-of-function mutations can trigger leukemogenesis remains unclear. Here, we demonstrate that lymphoid-restricted mutant IL7R, expressed at physiological levels in conditional knock-in mice, establishes a pre-leukemic stage in which B-cell precursors display self-renewal ability, initiating leukemia resembling PAX5 P80R or Ph-like human B-ALL. Full transformation associates with transcriptional upregulation of oncogenes such as Myc or Bcl2, downregulation of tumor suppressors such as Ikzf1 or Arid2, and major IL-7R signaling upregulation (involving JAK/STAT5 and PI3K/mTOR), required for leukemia cell viability. Accordingly, maximal signaling drives full penetrance and early leukemia onset in homozygous IL7R mutant animals. Notably, we identify 2 transcriptional subgroups in mouse and human Ph-like ALL, and show that dactolisib and sphingosine-kinase inhibitors are potential treatment avenues for IL-7R-related cases. Our model, a resource to explore the pathophysiology and therapeutic vulnerabilities of B-ALL, demonstrates that IL7R can initiate this malignancy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。